Watson Launches Generic PROMETRIUM(R)

  //health-fitness.news-articles.net/content/2012/03/02/watson-launches-generic-prometrium-r.html
  Published in Health and Fitness on Friday, March 2nd 2012 at 6:45 GMT by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

Watson Launches Generic PROMETRIUM(R) -- PARSIPPANY, N.J., March 2, 2012 /PRNewswire/ --

[ ]

My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about WPI

[ ]

[ Download image ]

PARSIPPANY, N.J., March 2, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: [ WPI ]) today confirmed that Watson has launched an authorized generic version of PROMETRIUM® (progesterone, USP) Capsules 100mg and 200mg, as part of an agreement with Abbott Laboratories. Watson began shipping the product today. PROMETRIUM® Capsules are indicated for use in the prevention of endometrial hyperplasia in non hysterectomized postmenopausal women who are receiving conjugated estrogen tablets. They are also indicated for use in secondary amenorrhea.

Under the terms of the supply agreement, Abbott manufactures and supplies Watson with all dosage strengths of the authorized generic product. Watson markets and distributes the product in the United States and the parties will share profits based on sales of the product. Other terms of the agreement have not been disclosed.

For the most recent twelve months ending January 31, 2012, PROMETRIUM® had sales of approximately $198 million, according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets. 

For press release and other company information, visit Watson Pharmaceuticals' Web site at [ http://www.watson.com ].

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business.  These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31, 2011. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

PROMETRIUM® is a registered trademark of Abbott Laboratories.   

(Logo: [ http://photos.prnewswire.com/prnh/20100121/LA41294LOGO ] )

SOURCE Watson Pharmaceuticals, Inc.

RELATED LINKS
[ http://www.watson.com ]